EX-99.2 3 dp71131_ex9902.htm EXHIBIT 99.2

Exhibit 99.2

 

 

Crenezumab exposure-response across AD endpoints supports a higher dose for Phase 3

Dan Polhamus PhD1, James Rogers PhD2, Robert Paul MD2, Smita Kshirsagar PhD2, Srikumar Sahasranaman PhD2, Jin Y Jin PhD2, Angelica L Quartino PhD2

(1) Metrum Research Group, Tariffville, CT. USA

(2) Genentech, Inc., San Francisco, CA. USA